Literature DB >> 26399557

Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.

Sarah J Woolsey1,2, Melanie D Beaton3, Yun-Hee Choi4, George K Dresser2, Steven E Gryn2, Richard B Kim1,2, Rommel G Tirona1,2.   

Abstract

Due to high basal interindividual variation in cytochrome P450 3A (CYP3A) activity and susceptibility to drug interactions, there has been interest in the application of efficient probe drug phenotyping strategies, as well as endogenous biomarkers for assessment of in vivo CYP3A activity. The biomarkers 4β-hydroxycholesterol (4βHC) and 6β-hydroxycortisol (6βHCL) are sensitive to CYP3A induction and inhibition. However, their utility for the assessment of constitutive CYP3A activity remains uncertain. We investigated whether endogenous plasma biomarkers (4βHC and 6βHCL) are associated with basal CYP3A metabolic activity in healthy subjects assessed by a convenient single-time-point oral midazolam (MDZ) phenotyping strategy. Plasma 4βHC and 6βHCL metabolic ratios (MRs) were analysed in 51 healthy adult participants. CYP3A activity was determined after administration of an oral MDZ microdose (100 μg). Simple linear and multiple linear regression analyses were performed to assess relationships between MDZ oral clearance, biomarkers and subject covariates. Among study subjects, basal MDZ oral clearance, 4βHC and 6βHCL MRs ranged 6.5-, 10- and 13-fold, respectively. Participant age and alcohol consumption were negatively associated with MDZ oral clearance (p = 0.03 and p = 0.045, respectively), while weight and female sex were associated with lower plasma 4βHC MR (p = 0.0003 and p = 0.032, respectively). Neither 4βHC nor 6βHCL MRs were associated with MDZ oral clearance. Plasma 4βHC and 6βHCL MRs do not relate to MDZ single-time-point metabolic phenotype in the assessment of constitutive CYP3A activity among healthy individuals.
© 2015 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26399557     DOI: 10.1111/bcpt.12492

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  10 in total

Review 1.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration.

Authors:  Kristine Hole; C Gjestad; K M Heitmann; T Haslemo; E Molden; S Bremer
Journal:  Eur J Clin Pharmacol       Date:  2016-12-14       Impact factor: 2.953

3.  Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.

Authors:  Thomas Vanhove; Mahmoud Hasan; Pieter Annaert; Stefan Oswald; Dirk R J Kuypers
Journal:  Br J Clin Pharmacol       Date:  2017-07-14       Impact factor: 4.335

4.  Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range.

Authors:  Kine Eide Kvitne; Kristine Hole; Veronica Krogstad; Birgit Malene Wollmann; Christine Wegler; Line K Johnson; Jens K Hertel; Per Artursson; Cecilia Karlsson; Shalini Andersson; Tommy B Andersson; Rune Sandbu; Jøran Hjelmesæth; Eva Skovlund; Hege Christensen; Rasmus Jansson-Löfmark; Anders Åsberg; Espen Molden; Ida Robertsen
Journal:  Eur J Clin Pharmacol       Date:  2022-06-01       Impact factor: 3.064

5.  Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.

Authors:  Thomas Vanhove; Hylke de Jonge; Henriëtte de Loor; Pieter Annaert; Ulf Diczfalusy; Dirk R J Kuypers
Journal:  Br J Clin Pharmacol       Date:  2016-09-20       Impact factor: 4.335

6.  Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients.

Authors:  Kristine Hole; Petra L Heiberg; Caroline Gjestad; Lise L Mehus; Øyvind Rø; Espen Molden
Journal:  Pharmacol Res Perspect       Date:  2018-09-11

7.  Association between low body weight and cytochrome P-450 enzyme activity in patients with anorexia nervosa.

Authors:  Pål Sandvik; Stian Lydersen; Solfrid Hegstad; Olav Spigset
Journal:  Pharmacol Res Perspect       Date:  2020-06

8.  Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn's disease.

Authors:  Aze Wilson; Ahmed Almousa; Wendy A Teft; Richard B Kim
Journal:  Sci Rep       Date:  2020-02-05       Impact factor: 4.379

9.  Studies on CYP3A activity during the menstrual cycle as measured by urinary 6β-hydroxycortisol/cortisol.

Authors:  Helena Bergström; Anna Lindahl; Anna Warnqvist; Ulf Diczfalusy; Lena Ekström; Linda Björkhem-Bergman
Journal:  Pharmacol Res Perspect       Date:  2021-12

10.  Mechanism Investigation of Rifampicin-Induced Liver Injury Using Comparative Toxicoproteomics in Mice.

Authors:  Ju-Hyun Kim; Woong Shik Nam; Sun Joo Kim; Oh Kwang Kwon; Eun Ji Seung; Jung Jae Jo; Riya Shresha; Tae Hee Lee; Tae Won Jeon; Sung Hwan Ki; Hye Suk Lee; Sangkyu Lee
Journal:  Int J Mol Sci       Date:  2017-07-02       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.